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Hallmark to most cancers is the muta-
tion or complete loss of function of the 
tumor-suppressor gene p53. p53 functions 
by transcriptionally activating or repress-
ing putative downstream targets to elicit a 
network of tumor-suppressive functions—
transient cell cycle arrest allowing for 
DNA repair and, upon irreparable dam-
age, senescence or apoptosis.1 Recently, our 
group has shown that p53-meidated trans-
activation of metabolic targets can sup-
press tumorigenesis in the absence of both 
cell cycle arrest and apoptosis.2 Notably 
termed the “guardian of the genome,” 
many therapies have been targeted to 
reactivate p53 or the downstream targets 
to initiate apoptosis or cell cycle arrest in 
cells that have escaped these properties, yet 
in some instances, p53-proficient tumors 
have a worse response to therapy.3 An 
opposite and ever-attractive chemothera-
peutic approach has been to selectively tar-
get attributes of p53-mutant and -deficient 
cells that are absent in p53 proficiency.
In 2004, Manuel Serrano’s group 
characterized a demethylating agent 
with the highest selective toxicity toward 
p53-deficient cells compared with other 
popular DNA-damaging agents.4 This 
demethylating agent, 5-aza-2'-deoxycyt-
idine (5-aza-dc), also called decitabine 
and marketed as Dacogen, has been 
recently FDA approved for the treatment 
of chronic myelomonocytic leukemia 
(CMML) and myelodysplastic syndrome 
(MDS) as well as showing promise with 
other tumor types.5-7 In the most recent 
issue of PNAS, Andrie Gudkov’s group 
elegantly elucidates a mechanism of action 
for p53-deficient cell death after 5-aza-dc 
treatment, highlighting potential markers 
to determine increased drug efficacy for 
different tumor types.8
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Initially, Leonova et al, confirmed the 
selective toxicity of the demethylating 
agent 5-aza-dc in proliferating p53-mutant 
and -deficient fibroblasts compared 
with wild-type controls8 as previously 
described.4 Microarray gene expression 
profiling using murine embryonic fibro-
blasts (MEFs) with and without p53 and 
drug treatment uncovered 55 genes nor-
mally repressed by p53 in a methylated 
state that were upregulated 5-fold upon 
hypomethylation. For the most part, these 
target mRNA only increased to the level 
of untreated p53−/−, suggesting that only 
in the presence of p53, DNA methylation 
helps suppress these targets. Interestingly, 
5-aza-dc treatment of p53-deficient MEFs 
strongly upregulated 124 genes, remain-
ing silent in drug-treated WT MEFs. The 
majority of these targets were classified 
as part of or downstream to the type I 
interferons (INF-α and -β).8 Classically, 
type I INFs signal through the INF cell-
surface receptor (IFNAR) to initiate a 
cellular cascade to enhance the immune 
response upon viral infections as well 
as regulate tumor cell survival.9 To con-
firm the dependency of a “suicidal” INF-
stimulated p53-deficient cell death after 
5-aza-dc treatment, IFNAR−/− MEFs 
were generated that lose the ability of 
stimulating a type I INF response. After 
hypomethylation, knocking down p53 in 
IFNAR−/− MEFs reversed the cell death 
seen in p53 deficiency alone, validating the 
hypothesis of INF-dependent cell death.
Leonova et al, next sought to pinpoint 
the trigger activating the “suicidal” INF 
response. Since the gene-expression profil-
ing did not uncover any plausible explana-
tion for the INF activation and is solely 
a read out of protein-coding mRNA, 
researchers intuitively utilized RNA 
sequencing.8 Moreover, INFs are classi-
cally activated upon double-stranded RNA 
typically from viral infections, increasing 
the likelihood that the candidate of the 
INF response would not be from a protein 
coding transcript. Intriguingly, 5-aza-dc-
treated p53−/− MEFs showed a significant 
abundance of three specific types of RNA 
transcripts produced 150-fold greater 
than β-actin mRNA.8 Once referred to 
as “junk DNA,” these repetitive elements 
are gaining more attraction in the recent 
years. Comprising two-thirds of the RNA 
transcripts produced from drug-treated 
p53−/− MEFs, are gamma satellite repeats 
(GSATs) transcribed from large tandem 
repeats of non-coding DNA near the cen-
tromeres and in heterochromatin as well 
as short interspersed elements (SINEs), 
which are short DNA sequences inter-
spersed throughout the genome. The other 
highly abundant classification of transcript 
is termed non-coding RNAs (ncRNA), 
simply characterized as an RNA that does 
not produce a protein product. The high 
abundance of these RNA transcripts has 
been proposed to form large amounts 
of dsRNA characteristic of a viral infec-
tion resulting in the activation of an INF 
response.
Lastly, murine tumor cell lines were 
treated with 5-aza-dc and probed for 
transcription of repeats. Samples with 
a strong induction of GSATs correlated 
with upregulated INF targets, IRF7 and 
CXCL10, as well as increased susceptibil-
ity to 5-aza-dc, while samples with low 
expression of these repetitive transcripts 
did not upregulate INF genes and were 
modestly resistant to drug treatment.8 
Spontaneous thymic lymphomas arising 
from p53-deficient mice had increased 
GSAT and IFN expression when compared 
10 Cell Cycle Volume 12 issue 1
the high rate of p53 abrogation, many 
tumors may have developed resistance to 
INF-mediated death. Although further 
investigation is needed to elucidate in 
vivo efficacy, tumors may be pre-screened 
for p53 status, increased transcription of 
repeats and an intact INF response; these 
criteria will allow a free TRAIN ride to 
cell death.
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with p53−/− non-tumorigenic thymi. The 
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described here as “TRAIN” (transcription 
of repeats activates interferon). The model 
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depicted in Figure 1, demonstrates a novel 
role for p53 as the “guardian of repeats,” 
where, in cooperation with DNA methyla-
tion, transcriptionally silences repetitive 
DNA segments, which otherwise activate 
a “suicidal” interferon response leading to 
apoptotic cell death.
With this newly discovered mecha-
nism, 5-aza-dc may become a more attrac-
tive therapeutic target for many cancers 
that have mutated or complete p53 inac-
tivation. Since some tumors exhibit global 
hypomethylation, taken in concert with 
Figure 1. schematic of traiN (transcription of repeats activates interferon)-induced cell death. in a hypomethylated state (caused from 5-aza-dc 
treatment), p53 suppresses the transcription of repetitive factors (siNE, Gsat, nc-rNa), which presumably form into double-stranded rNa to activate a 
“suicidal” interferon response leading to apoptosis specifically in a p53-deficient setting.
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